...
首页> 外文期刊>BMC Cancer >Digital imaging in the immunohistochemical evaluation of the proliferation markers Ki67, MCM2 and Geminin, in early breast cancer, and their putative prognostic value
【24h】

Digital imaging in the immunohistochemical evaluation of the proliferation markers Ki67, MCM2 and Geminin, in early breast cancer, and their putative prognostic value

机译:免疫组化中数字成像对早期乳腺癌中增殖标志物Ki67,MCM2和Geminin的免疫组化评价及其预后价值

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Background Immunohistochemical assessment of proliferation may provide additional prognostic information in early breast cancer. However, due to a lack of methodological standards proliferation markers are still not routinely used for determining therapy. Even for Ki67, one of the most widely-studied markers, disagreements over the optimal cutoff exist. Improvements in digital microscopy may provide new avenues to standardise and make data more reproducible. Methods We studied the immunohistochemical expression of three markers of proliferation: Ki67, Mini-Chromosome Maintenance protein 2 and Geminin, by conventional light microscope and digital imaging on triplicate TMAs from 309 consecutive cases of primary breast cancers. Differences between the average and the maximum percentage reactivity in tumour cell nuclei from the three TMA cores were investigated to assess the validity of the approach. Time-dependent Receiver Operating Characteristic curves were utilized to obtain optimal expression level cut-offs, which were then correlated with clinico-pathological features and survival. Results High concordance between conventional and digital scores was observed for all 3 markers (Ki67: rs?=?0.87, P s?=?0.94, P s?=?0.86, P Conclusions Here we show that. MCM2 is a more sensitive marker of proliferation than Ki67 and should be examined in future studies, especially in the lymph node-negative, hormone receptor-positive subgroup. Further, digital microscopy can be used effectively as a high-throughput method to evaluate immunohistochemical expression.
机译:背景增殖的免疫组织化学评估可能会为早期乳腺癌提供更多的预后信息。然而,由于缺乏方法学标准,增殖标记物仍未常规用于确定治疗。即使对于Ki67(研究最广泛的标志之一),也存在关于最佳截止值的分歧。数字显微镜的改进可能提供标准化和使数据更可重现的新途径。方法我们通过常规光学显微镜和数字成像技术,对连续309例原发性乳腺癌患者的一式三份TMA进行了研究,研究了三种增殖标志物Ki67,微染色体维持蛋白2和Geminin的免疫组织化学表达。研究了来自三个TMA核心的肿瘤细胞核中平均反应活性百分比和最大反应活性百分比之间的差异,以评估该方法的有效性。利用随时间变化的受体工作特征曲线获得最佳的表达水平临界值,然后将其与临床病理特征和生存期相关联。结果观察到所有三个标记(Ki67:r s ?=?0.87,P s ?=?0.94,P s ?= 0.8 0.86,P结论我们在这里表明:MCM2是比Ki67更敏感的增殖标志物,应在以后的研究中进行检查,尤其是在淋巴结阴性,激素受体阳性的亚组中,此外,数字显微镜可以有效地使用。作为评估免疫组织化学表达的高通量方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号